[Feature Stock] Y2Solution Secures Lead in Robot Charging Power Modules... Acquires Partner of World's No.1 Collaborative Robot Company

Y2Solution is showing strong performance. The news that the company has acquired HRT Robotics, a robot system integration (SI) specialist, appears to be influencing its stock price. HRT is the first official domestic partner of Universal Robots, the world's leading collaborative robot manufacturer.

As of 9:25 a.m. on June 10, Y2Solution was trading at 3,780 won, up 16.13% from the previous day.

HRT provides robot automation design and supply tailored to the manufacturing environments of its clients. It is recognized as an automation solutions company with capabilities in integrating control systems, vision cameras, and autonomous mobile robots (AMR). The company is currently developing its own autonomous mobile robot.

Universal Robots was the first company in the world to commercialize collaborative robots and holds a 40% share of the global market. It is a subsidiary of Teradyne, a Nasdaq-listed company with a market capitalization of approximately 19 trillion won. Universal Robots plays a central role in the global automation ecosystem, including collaborative robots and autonomous mobile robots.

By acquiring HRT, Y2Solution will add robot SI capabilities to its existing power supply unit (PSU) business and enter the industrial collaborative robot and robot integration solutions market. Based on its high-efficiency power module development technology, the company also plans to expand its business into the field of charging power modules for robots in the future.

Kang Seokhwan, CEO of Y2Solution, stated, "The significance lies in securing core competencies for the implementation of future manufacturing industries, such as smart factories, along with our entry into the robot SI business." He added, "We plan to expand our business scope to include robots, leveraging the synergy from the HRT acquisition." He further emphasized, "We aim to establish ourselves as a competitive company in the fields of charging power modules and SI solutions for robots."

Y2Solution is also conducting global clinical trials for a treatment for dry age-related macular degeneration through its U.S. joint venture, LuxaBio. The company’s strategy is to enhance its mid- to long-term corporate value by pursuing a two-track growth model focused on both robotics and biotechnology, based on its stable and profitable existing business.